Alnylam Pharmaceuticals, Inc. ALNY
NASDAQ
| 09/30/2026 | 06/30/2026 | ||||
|---|---|---|---|---|---|
| Revenue | 12.95% | 10.60% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 12.95% | 10.60% | |||
| Cost of Revenue | 21.21% | 41.36% | |||
| Gross Profit | 10.46% | 3.81% | |||
| SG&A Expenses | -1.70% | 7.87% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 4.98% | 17.91% | |||
| Operating Income | 49.41% | -13.85% | |||
| Income Before Tax | 66.37% | -19.78% | |||
| Income Tax Expenses | -14,158.93% | -15.00% | |||
| Earnings from Continuing Operations | 1,217.58% | -20.15% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 1,217.58% | -20.15% | |||
| EBIT | 49.41% | -13.85% | |||
| EBITDA | 46.85% | -13.06% | |||
| EPS Basic | 1,215.38% | -20.57% | |||
| Normalized Basic EPS | 66.09% | -20.20% | |||
| EPS Diluted | 1,198.82% | -19.78% | |||
| Normalized Diluted EPS | 66.66% | -19.82% | |||
| Average Basic Shares Outstanding | 0.17% | 0.54% | |||
| Average Diluted Shares Outstanding | -0.17% | 0.04% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||